Maha H.A. Hussain, MD, on Castration-Resistant Prostate Cancer: Future Directions for PARP Inhibitors

Posted: Monday, October 7, 2019

Maha H.A. Hussain, MD, of Northwestern University Robert H. Lurie Comprehensive Cancer Center, discusses the findings of the PROfound trial with olaparib in metastatic castration-resistant prostate cancer, and other PARP inhibitors that are likely to be studied in this setting.